Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Daiichi Sankyo
Healthtrust
Argus Health
Chinese Patent Office
McKinsey
Deloitte
Julphar
AstraZeneca

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,871,813

« Back to Dashboard

Which drugs does patent 8,871,813 protect, and when does it expire?

Patent 8,871,813 protects PROLENSA and is included in one NDA.

This patent has seventeen patent family members in thirteen countries.
Summary for Patent: 8,871,813
Title:Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).
Inventor(s): Sawa; Shirou (Hyogo, JP), Fujita; Shuhei (Hyogo, JP)
Assignee: Senju Pharmaceutical Co., Ltd. (Osaka, JP)
Application Number:14/261,720
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,871,813
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 8,871,813

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bausch And Lomb PROLENSA bromfenac sodium SOLUTION/DROPS;OPHTHALMIC 203168-001 Apr 5, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,871,813

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2003-012427Jan 21, 2003

Non-Orange Book US Patents Family Members for Patent 8,871,813

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,561,277 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid ➤ Sign Up
8,669,290 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid ➤ Sign Up
8,129,431 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid ➤ Sign Up
9,144,609 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
QuintilesIMS
Moodys
Boehringer Ingelheim
Argus Health
Baxter
Cerilliant
Citi
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.